Posts

Gene editor Scribe Therapeutics starts second-half IPO spree with $129M listing

on

FDA deepens Vertex's Casgevy label to include patients as young as 2

on

Scribe Therapeutics preps IPO to fund lipid‑lowering genetic medicines through clinical trials

on

China gene editing startup YolTech raises $70M to move CRISPR therapies forward

on

Taking the temperature on new and emerging SCD therapies

on

CRISPR Therapeutics Reports Q1 2026 Financial Results with CASGEVY Revenue of $43M and $2.44B Cash Position

on

Intellia Therapeutics Advances In Vivo CRISPR Therapy Lonvo-z to FDA After Positive Phase 3 HAELO Trial Results

on

FDA Fully Lifts Clinical Hold on Intellia Therapeutics' CRISPR Gene Therapy Trials for ATTR Amyloidosis

on

FDA Lifts Clinical Hold on Intellia's MAGNITUDE-2 Phase 3 Trial for Nex-Z in ATTRv-PN

on

CRISPR Pioneers Jennifer Doudna and Fyodor Urnov Launch Aurora Therapeutics for Custom CRISPR Therapies

on

CRISPR Pioneers Jennifer Doudna and Fyodor Urnov Launch Aurora Therapeutics for Custom CRISPR Therapies

on

CRISPR Pioneers Jennifer Doudna and Fyodor Urnov Launch Aurora Therapeutics for Custom CRISPR Therapies

on

FDA Unveils 'Plausible Mechanism Pathway' to Accelerate Personalized Therapies, Inspired by Baby KJ

on

Intellia Pauses Two CRISPR Trials After Severe Liver Toxicity Hospitalizes Patient

on

NanoPhoria Secures €83.5M Series A for Heart Failure Therapy; AstraZeneca and Algen Ink Up to $555M AI Drug Discovery Pact

on

Post-Hoc: AI bio needs to heed the overhyped history of CRISPR

on

CRISPR Therapeutics Partners with Sirius for siRNA Therapies, Expanding Beyond Gene Editing

on

Federal Appeals Court Revives CRISPR Patent Dispute Between Broad Institute and University of California

on

CRISPR Therapeutics' gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%

on

Caribou cuts 32% of staff, further purges pipeline to focus on 2 oncology CAR-T prospects

on